Asset Details
Do you wish to reserve the book?
Hematological toxicity of anti-tumor antibody-drug conjugates: A retrospective pharmacovigilance study using the FDA adverse event reporting system
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Hematological toxicity of anti-tumor antibody-drug conjugates: A retrospective pharmacovigilance study using the FDA adverse event reporting system
Do you wish to request the book?
Hematological toxicity of anti-tumor antibody-drug conjugates: A retrospective pharmacovigilance study using the FDA adverse event reporting system
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Hematological toxicity of anti-tumor antibody-drug conjugates: A retrospective pharmacovigilance study using the FDA adverse event reporting system
2025
Overview
Although antibody-drug conjugates (ADCs) have shown significant efficacy in cancer treatment, hematotoxicity remains a serious issue. This study aims to investigate the relationship between ADCs and hematological toxicity. Our study was conducted using data extracted from the U.S. Food and Drug Administration Adverse Events Reporting System (FAERS) from the third quarter of 2011 to the second quarter of 2024. We used four disproportionality analysis methods to measure risk signals. In addition, we analyzed the time-to-onset of hematotoxicity adverse events (AEs). A total of 4,803 cases of hematotoxicity AEs associated with ADCs were identified, the median age of patients was 60 years (IQR: 47-72). Different ADCs have different hematotoxicity profiles, among which brentuximab vedotin (BV) and sacituzumab govitecan (SG) were more likely to lead to serious outcomes. The median time-to-onset of hematotoxicity AEs was the shortest for SG at 12 days and the longest for trastuzumab deruxtecan (TG) at 22 days. The hospitalization and mortality rates with hematotoxicity AEs were 30.38% and 18.30%, respectively. ADCs are significantly associated with increased reporting of hematotoxicity. A novel hematotoxicity signal that was not disclosed in the drug specifications was observed. The most prominent hematotoxicity AE signals were cytopenia related to inotuzumab ozogamicin (IO), polatuzumab vedotin (PV), loncastuximab tesirine (LT), and tisotumab vedotin (TV); febrile bone marrow aplasia related togemtuzumab ozogamicin (GO), BV, and SG; and myelosuppression related to BV, trastuzumab emtansine (TE), andenfortumab vedotin (EV). Our findings need to be validated by large-scale prospective studies.
Publisher
Public Library of Science,Public Library of Science (PLoS)
We currently cannot retrieve any items related to this title. Kindly check back at a later time.